The HEARTS partner forum-supporting implementation of HEARTS to treat and control hypertension.

cardiovascular diseases global health health systems hypertension implementation partnerships primary healthcare universal health coverage

Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2023
Historique:
received: 24 03 2023
accepted: 03 07 2023
medline: 10 8 2023
pubmed: 9 8 2023
entrez: 9 8 2023
Statut: epublish

Résumé

Cardiovascular diseases (CVD), principally ischemic heart disease (IHD) and stroke, are the leading causes of death (18. 6 million deaths annually) and disability (393 million disability-adjusted life-years lost annually), worldwide. High blood pressure is the most important preventable risk factor for CVD and deaths, worldwide (10.8 million deaths annually). In 2016, the World Health Organization (WHO) and the United States Centers for Disease Control (CDC) launched the Global Hearts initiative to support governments in their quest to prevent and control CVD. HEARTS is the core technical package of the initiative and takes a public health approach to treating hypertension and other CVD risk factors at the primary health care level. The HEARTS Partner Forum, led by WHO, brings together the following 11 partner organizations: American Heart Association (AHA), Center for Chronic Disease Control (CCDC), International Society of Hypertension (ISH), International Society of Nephrology (ISN), Pan American Health Organization (PAHO), Resolve to Save Lives (RTSL), US CDC, World Hypertension League (WHL), World Heart Federation (WHF) and World Stroke Organization (WSO). The partners support countries in their implementation of the HEARTS technical package in various ways, including providing technical expertise, catalytic funding, capacity building and evidence generation and dissemination. HEARTS has demonstrated the feasibility and acceptability of a public health approach, with more than seven million people already on treatment for hypertension using a simple, algorithmic HEARTS approach. Additionally, HEARTS has demonstrated the feasibility of using hypertension as a pathfinder to universal health coverage and should be a key intervention of all basic benefit packages. The partner forum continues to find ways to expand support and reinvigorate enthusiasm and attention on preventing CVD. Proposed future HEARTS Partner Forum activities are related to more concrete information sharing between partners and among countries, expanded areas of partner synergy, support for implementation, capacity building, and advocacy with country ministries of health, professional societies, academy and civil societies organizations. Advancing toward the shared goals of the HEARTS partners will require a more formal, structured approach to the forum and include goals, targets and published reports. In this way, the HEARTS Partner Forum will mirror successful global partnerships on communicable diseases and assist countries in reducing CVD mortality and achieving global sustainable development goals (SDGs).

Identifiants

pubmed: 37554732
doi: 10.3389/fpubh.2023.1146441
pmc: PMC10405076
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1146441

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2023 Khan, Moran, Perel, Whelton, Brainin, Feigin, Kostova, Richter, Ordunez, Hennis, Lackland, Slama, Pineiro, Martins, Williams, Hofstra, Garg and Mikkelsen.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet. 2021 Sep 11;398(10304):957-980
pubmed: 34450083
Rev Panam Salud Publica. 2022 Jul 16;46:e96
pubmed: 35855441
J Clin Hypertens (Greenwich). 2020 Oct;22(10):1769-1779
pubmed: 32815663
Hypertension. 2022 Jan;79(1):293-301
pubmed: 34775787
J Clin Hypertens (Greenwich). 2020 Feb;22(2):142-149
pubmed: 31967722
Lancet. 2020 Sep 26;396(10255):918-934
pubmed: 32891217
BMJ Open. 2022 Jun 27;12(6):e061467
pubmed: 35760540
Hypertension. 2021 Mar 3;77(3):806-812
pubmed: 33517681
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32912853
Rev Port Cardiol (Engl Ed). 2020 Jan;39(1):27-34
pubmed: 32143997
Rev Panam Salud Publica. 2022 Sep 02;46:e140
pubmed: 36071923
Nat Med. 2022 Aug;28(8):1693-1699
pubmed: 35851877
J Clin Hypertens (Greenwich). 2020 Aug;22(8):1296-1309
pubmed: 33289261
BMC Public Health. 2018 Jun 11;18(1):722
pubmed: 29890937
Can J Cardiol. 2021 May;37(5):744-755
pubmed: 33310142
Rev Panam Salud Publica. 2022 Sep 17;46:e165
pubmed: 36128471
J Hum Hypertens. 2023 Jul;37(7):560-567
pubmed: 35945426
Lancet Reg Health Am. 2022 May;9:None
pubmed: 35711684
Lancet. 2022 Mar 26;399(10331):1266-1278
pubmed: 35339227
Rev Panam Salud Publica. 2022 Sep 15;46:e144
pubmed: 36128473
J Clin Hypertens (Greenwich). 2021 Apr;23(4):755-765
pubmed: 33738969
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175

Auteurs

Taskeen Khan (T)

Department of Non-communicable Diseases, World Health Organization, Geneva, Switzerland.

Andrew E Moran (AE)

Resolve to Save Lives, New York, NY, United States.
Department of Medicine, Columbia University, New York, NY, United States.

Pablo Perel (P)

Centre for Global Chronic Conditions, Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
World Heart Federation, Geneva, Switzerland.

Paul K Whelton (PK)

Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States.
World Hypertension League, New Orleans, LA, United States.

Michael Brainin (M)

Department of Clinical Neurology, Danube University, Krems, Austria.
World Stroke Organization, Geneva, Switzerland.

Valery Feigin (V)

World Stroke Organization, Geneva, Switzerland.
National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand.

Deliana Kostova (D)

Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Non-communicable Diseases and Mental Health, Atlanta, GA, United States.

Patricia Richter (P)

Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Non-communicable Diseases and Mental Health, Atlanta, GA, United States.

Pedro Ordunez (P)

Pan American Health Organization/World Health Organization, Washington, DC, United States.

Anselm Hennis (A)

Pan American Health Organization/World Health Organization, Washington, DC, United States.

Daniel T Lackland (DT)

World Hypertension League, New Orleans, LA, United States.
Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC, United States.

Slim Slama (S)

Department of Non-communicable Diseases, World Health Organization, Geneva, Switzerland.

Daniel Pineiro (D)

World Heart Federation, Geneva, Switzerland.
Universidad de Buenos Aires, Buenos Aires, Argentina.

Sheila Martins (S)

World Stroke Organization, Geneva, Switzerland.
Universidade Federal of Rio Grande do Sul, Porto Alegre, Brazil.

Bryan Williams (B)

International Society of Hypertension, Essex, United Kingdom.

Leonard Hofstra (L)

Amsterdam UMC-Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Renu Garg (R)

Resolve to Save Lives, New York, NY, United States.

Bente Mikkelsen (B)

Department of Non-communicable Diseases, World Health Organization, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH